Literature DB >> 26308316

Prevalence of Peripheral Eosinophilia at Diagnosis in Children With Inflammatory Bowel Disease.

Geetanjalee Sadi1, Qi Yang, Brenden Dufault, Camelia Stefanovici, Jayson Stoffman, Wael El-Matary.   

Abstract

BACKGROUND AND
OBJECTIVE: Inflammatory bowel disease (IBD) encompasses 2 disorders of unknown etiology: Crohn disease (CD) and ulcerative colitis (UC). There has been a continuous search for markers for disease activity. Eosinophils are granulocytic leukocytes that are implicated in the pathogenesis of IBD. The aim of this study was to examine the prevalence and significance of peripheral eosinophilia (PE) at diagnosis in children with IBD.
METHODS: A comprehensive chart review of all children with diagnosed as having IBD between January 2006 and August 2014 was performed. Patients with PE at diagnosis were compared with those without in relation to disease clinical activity and disease course.
RESULTS: A total of 109 children (mean age 14.6 ± 2.77, range 4.5-17.9 years, 55 boys) with IBD (68 with CD and 41 with UC) who were studied for a mean duration of 2.82 ± 1.89 (range 0.1-9.2 years) were identified. At diagnosis, 44 (40.4%) children had PE, which was more prevalent in patients with UC compared with those with CD (61.3% vs 36.3%, P < 0.05). At diagnosis, PE was more common in patients with high eosinophilic count in colonic biopsy samples (P < 0.01) and was significantly associated with disease activity as indicated by Pediatric CD Activity Index for children with CD (P < 0.05), Pediatric UC Activity Index for children with UC (P < 0.01).
CONCLUSIONS: PE is a common finding at diagnosis in children with IBD especially in those with UC. Patients with PE at diagnosis are more likely to present with higher clinical activity indices. PE is associated with more eosinophils in colonic biopsy samples.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26308316     DOI: 10.1097/MPG.0000000000000957

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  5 in total

1.  Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes.

Authors:  Douglas Zabrowski; Danielle Abraham; Geoffrey Rosenthal; Howard Kader
Journal:  JGH Open       Date:  2020-02-07

2.  Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype.

Authors:  Benjamin Click; Alyce M Anderson; Ioannis E Koutroubakis; Claudia Ramos Rivers; Dmitriy Babichenko; Jorge D Machicado; Douglas J Hartman; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Sally E Wenzel; Miguel Regueiro; David G Binion
Journal:  Am J Gastroenterol       Date:  2017-11-07       Impact factor: 10.864

3.  Increased Prevalence of Esophageal Eosinophilia in Patients with Inflammatory Bowel Disease.

Authors:  Y Claire Fan; David Steele; Bharati Kochar; Diana Arsene; Millie D Long; Evan S Dellon
Journal:  Inflamm Intest Dis       Date:  2019-03-20

Review 4.  Eosinophils in Autoimmune Diseases.

Authors:  Nicola L Diny; Noel R Rose; Daniela Čiháková
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

5.  Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD.

Authors:  Katarzyna Neubauer; Malgorzata Matusiewicz; Iwona Bednarz-Misa; Sabina Gorska; Andrzej Gamian; Malgorzata Krzystek-Korpacka
Journal:  Gastroenterol Res Pract       Date:  2018-07-29       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.